Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC explains why the use of molecular analysis to determine therapy choice is more of a hope to society. He argues that it is not ready for clinical use and discusses the current NCI-MATCH trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Molecular Analysis to Determine Therapy Choice Not Ready for Primetime
